Literature DB >> 20108111

Stepwise progression of pulmonary adenocarcinoma--clinical and molecular implications.

Masayuki Noguchi1.   

Abstract

Stepwise progression of pulmonary adenocarcinoma is described from the viewpoint of both pathology and molecular biology. Pulmonary adenocarcinoma develops to invasive carcinoma through atypical adenomatous hyperplasia, adenocarcinoma in situ and minimally invasive adenocarcinoma. The Noguchi classification is well correlated with this sequential histological progression. On the other hand, in terms of molecular biology, p16 gene inactivation, EGFR mutation and KRAS mutation are early events, and tumors progress to invasive adenocarcinoma as a result of p53 mutation, loss of various chromosomes and other genetic abnormalities.

Entities:  

Mesh:

Year:  2010        PMID: 20108111     DOI: 10.1007/s10555-010-9210-y

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  35 in total

Review 1.  Should we continue to use the term non-small-cell lung cancer?

Authors:  A F Gazdar
Journal:  Ann Oncol       Date:  2010-10       Impact factor: 32.976

2.  The evolving role of the pathologist in the management of lung cancer.

Authors:  Adi F Gazdar
Journal:  Lung Cancer Manag       Date:  2012

3.  Stepwise Disease Progression Model of Subsolid Lung Adenocarcinoma with Cystic Airspaces.

Authors:  Woohyun Jung; Sukki Cho; Sungwon Yum; Jin-Haeng Chung; Kyung Won Lee; Kwhanmien Kim; Choon Taek Lee; Sanghoon Jheon
Journal:  Ann Surg Oncol       Date:  2020-05-03       Impact factor: 5.344

Review 4.  Do all lung adenocarcinomas follow a stepwise progression?

Authors:  Yasushi Yatabe; Alain C Borczuk; Charles A Powell
Journal:  Lung Cancer       Date:  2011-06-25       Impact factor: 5.705

5.  Influenza A Virus Infection Triggers Pyroptosis and Apoptosis of Respiratory Epithelial Cells through the Type I Interferon Signaling Pathway in a Mutually Exclusive Manner.

Authors:  SangJoon Lee; Mikako Hirohama; Masayuki Noguchi; Kyosuke Nagata; Atsushi Kawaguchi
Journal:  J Virol       Date:  2018-06-29       Impact factor: 5.103

6.  Size matters: sequential mutations in tumorigenesis may reflect the stochastic effect of mutagen target sizes.

Authors:  Kimberly Long; Toaa Abuelenen; Libia Pava; Maya Bastille; George Blanck
Journal:  Genes Cancer       Date:  2011-10

7.  Field cancerization in non-small cell lung cancer: implications in disease pathogenesis.

Authors:  Humam Kadara; Ignacio I Wistuba
Journal:  Proc Am Thorac Soc       Date:  2012-05

8.  p53 loss does not permit escape from BrafV600E-induced senescence in a mouse model of lung cancer.

Authors:  S Garnett; K L Dutchak; R V McDonough; D Dankort
Journal:  Oncogene       Date:  2017-07-24       Impact factor: 9.867

9.  The Kinome of Human Alveolar Type II and Basal Cells, and Its Reprogramming in Lung Cancer.

Authors:  Sonia M Leach; Jay Finigan; Vihas T Vasu; Rangnath Mishra; Moumita Ghosh; Daniel Foster; Robert Mason; Beata Kosmider; Eveline Farias Hesson; Jeffrey A Kern
Journal:  Am J Respir Cell Mol Biol       Date:  2019-10       Impact factor: 6.914

Review 10.  C4.4A as a biomarker in pulmonary adenocarcinoma and squamous cell carcinoma.

Authors:  Benedikte Jacobsen; Mette Camilla Kriegbaum; Eric Santoni-Rugiu; Michael Ploug
Journal:  World J Clin Oncol       Date:  2014-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.